ArticleBritish journal of cancer2023
Five-year survival of patients with late-stage prostate cancer: comparison of the Military Health System and the U.S. general population.
Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Circulating Cell-Free miR-25-3p Is Upregulated in Brazilian Patients with Prostate Cancer and Contributes to Tumor Aggressiveness.Non-coding RNA · 2026Article
- Beyond EMT: Mesenchymal drift as an emerging driver of stromal-immune reprogramming in prostate cancer.iScience · 2026Review
- Relationship between Prostate Cancer and Benign Hyperplasia: Role of Inflammation-Induced Oxidative Stress, Vitamin C, and Epigenetics.The world journal of men's health · 2026Review
- NCBP2 Regulates PGAM5-Mediated Mitophagy Via KIF23 Alternative Splicing To Promote Cervical Cancer ProgressionRun Title: NCBP2 Promotes Cervical Cancer Via Mitophagy.Applied biochemistry and biotechnology · 2026Article
- NBPF1 acts as a tumor suppressor in prostate cancer by regulating the PI3K/AKT pathway.Archives of medical science : AMS · 2026Article
- A Miniaturized Optical Bioassay Towards Early-Stage Diagnosis of Cancer Using Immunosensing of Biomarkers (CA 15.3, PSA and CEA) by Toluidine Blue-Decorated Poly(Methyl Methacrylate): Proof of Concept.Analytical science advances · 2025Article
- Article
- Research landscape of hydroxamic acid hybrids with therapeutic potential against prostate cancer: a decade of advances.Future medicinal chemistry · 2025Review
- Testing the accuracy of a three-miRNA panel for the detection of primary prostate cancer: a discovery and validation study.Future oncology (London, England) · 2025Article
- Applications and Outcomes of Telehealth and Integrated Care in Men's Health Urology.Journal of medical Internet research · 2025Article
- Electrochemical Detection of Prostate Cancer-Associated miRNA-141 Using a Low-Cost Disposable Biosensor.Biosensors · 2025Article
- Understanding Racial Disparities in Prostate Cancer: A Multifaceted Approach.Cancer medicine · 2025Review
- Development and validation of a 16-gene T-cell- related prognostic model in non-small cell lung cancer.Frontiers in immunology · 2025Article
- CPT1A mediates the succinylation of SP5 which activates transcription of PDPK1 to promote the viability and glycolysis of prostate cancer cells.Cancer biology & therapy · 2024Article
- The Influence of β-Carotene and Its Liposomal Form on the Expression of EMT Markers and Androgen-Dependent Pathways in Different Prostate Cell Lines.Antioxidants (Basel, Switzerland) · 2024Article
- Versatile Design of Organic Polymeric Nanoparticles for Photodynamic Therapy of Prostate Cancer.ACS materials Au · 2024Review
- Leveraging Machine Learning Models to Explore Disparities in Prostate Cancer Diagnosis, Treatment, and Survival.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile the 5-year survival rate for local and regional prostate cancer is nearly 100%, it decreases dramatically for advanced tumours. Accessibility to health care is an important factor for cancer prognosis. The U.S. Military Health System (MHS) provides universal health care to its beneficiaries, reducing financial barriers to medical care. However, whether the universal care translates into improved survival among patients with advanced prostate cancer in the MHS is unknown. In this study, we compared the MHS and the U.S. general population in survival of patients with advanced prostate cancer (stages III and IV).
methodsThe MHS patients (N = 5379) were identified from the Department of Defense's (DoD) Automated Central Tumor Registry (ACTUR). Patients in the U.S. general population (N = 21,516) were identified from the Surveillance, Epidemiology, and End Results (SEER) programme. The two populations were matched on age, race, and diagnosis year.
resultsThe ACTUR patients exhibited longer 5-year survival than the matched SEER patients (HR = 0.74, 95% CI = 0.67-0.83), after adjustment for the potential confounders. The improved survival was observed for ages 50 years or older, both White patients and Black patients, all tumour stages and grades. This was also demonstrated despite the receipt of surgery or radiation treatment.
conclusionsMHS beneficiaries with advanced prostate cancer had longer survival than their counterparts in the U.S. general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.